文献速递糖尿病

司美格鲁肽联合基础胰岛素治疗2型糖尿病(SUSTAIN 5):随机对照试验

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

SUSTAIN 5是一项3a期双盲安慰剂对照30周试验,纳入397例基础胰岛素控制不佳的2型糖尿病患者,比较每周一次司美格鲁肽0.5mg或1.0mg与安慰剂的疗效。结果显示司美格鲁肽显著降低HbA1c和体重,严重或血糖确证低血糖发生率与安慰剂无显著差异,因不良事件停药率高于安慰剂,主要归因于胃肠道反应。

要点

  • 司美格鲁肽0.5mg和1.0mg较安慰剂显著降低HbA1c达1.4%和1.8%,安慰剂仅0.1%。
  • 司美格鲁肽0.5mg和1.0mg较安慰剂显著降低体重3.7kg和6.4kg,安慰剂1.4kg。
  • 严重或血糖确证低血糖发生率与安慰剂无显著差异,因不良事件停药率高于安慰剂。

核心结论

  • 在基础胰岛素控制不佳的2型糖尿病患者中,加用司美格鲁肽较安慰剂显著降低HbA1c和体重。

研究设计与样本

  • 3a期、双盲、安慰剂对照、30周试验,纳入397例接受稳定基础胰岛素治疗(联合或不联合二甲双胍)且血糖控制不佳的2型糖尿病患者。
  • 干预为皮下注射司美格鲁肽0.5mg或1.0mg每周一次,或体积匹配的安慰剂。
  • 研究在5个国家的90个中心进行。

主要发现

  • 第30周时,司美格鲁肽0.5mg和1.0mg组HbA1c分别降低1.4%(15.8 mmol/mol)和1.8%(20.2 mmol/mol),安慰剂组降低0.1%(1.0 mmol/mol)。
  • 司美格鲁肽0.5mg和1.0mg组体重分别降低3.7kg和6.4kg,安慰剂组降低1.4kg。
  • 严重或血糖确证低血糖:司美格鲁肽0.5mg组11例(17次事件),1.0mg组14例(25次事件),安慰剂组7例(13次事件)。
  • 因不良事件提前停药率:司美格鲁肽0.5mg组4.5%,1.0mg组6.1%,安慰剂组0.8%,主要归因于胃肠道疾病。

关键数值与推荐

  • HbA1c较安慰剂估计治疗差异:0.5mg组-1.35%(95% CI -1.61至-1.10),1.0mg组-1.75%(95% CI -2.01至-1.50),均P<0.0001。
  • 体重较安慰剂估计治疗差异:0.5mg组-2.31kg(95% CI -3.33至-1.29),1.0mg组-5.06kg(95% CI -6.08至-4.04),均P<0.0001。
  • 低血糖估计率比:0.5mg组2.08(95% CI 0.67至6.51),1.0mg组2.41(95% CI 0.84至6.96),均P=无显著性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Combination therapy with insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is important for treating type 2 diabetes (T2D). This trial assesses the efficacy and safety of semaglutide, a GLP-1RA, as an add-on to basal insulin. OBJECTIVE: To demonstrate the superiority of semaglutide vs placebo on glycemic control as an add-on to basal insulin in patients with T2D. DESIGN: Phase 3a, double-blind, placebo-controlled, 30-week trial. SETTING: This study included 90 sites in five countries. PATIENTS: We studied 397 patients with uncontrolled T2D receiving stable therapy with basal insulin with or without metformin. INTERVENTIONS: Subcutaneous semaglutide 0.5 or 1.0 mg once weekly or volume-matched placebo. MAIN OUTCOME MEASURES: Primary endpoint was change in glycated Hb (HbA1c) from baseline to week 30. Confirmatory secondary endpoint was change in body weight from baseline to week 30. RESULTS: At week 30, mean HbA1c reductions [mean baseline value, 8.4% (67.9 mmol/mol)] with semaglutide 0.5 and 1.0 mg were 1.4% (15.8 mmol/mol) and 1.8% (20.2 mmol/mol) vs 0.1% (1.0 mmol/mol) with placebo [estimated treatment difference (ETD) vs placebo, -1.35 (14.8 mmol/mol); 95% CI, -1.61 to -1.10 and ETD, -1.75% (19.2 mmol/mol); 95% CI, -2.01 to -1.50; both P < 0.0001]. Severe or blood glucose-confirmed hypoglycemic episodes were reported in 11 patients (17 events) and 14 patients (25 events) with semaglutide 0.5 and 1.0 mg, respectively, vs seven patients (13 events) with placebo (estimated rate ratio vs placebo, 2.08; 95% CI, 0.67 to 6.51 and estimated rate ratio vs placebo, 2.41; 95% CI, 0.84 to 6.96 for 0.5 and 1.0 mg; both P = nonsignificant). Mean body weight decreased with semaglutide 0.5 and 1.0 mg vs placebo from baseline to end of treatment: 3.7, 6.4, and 1.4 kg (ETD, -2.31; 95% CI, -3.33 to -1.29 and ETD, -5.06; 95% CI, -6.08 to -4.04 kg; both P < 0.0001). Premature treatment discontinuation due to adverse events was higher for semaglutide 0.5 and 1.0 mg vs placebo (4.5%, 6.1%, and 0.8%), mainly due to gastrointestinal disorders. CONCLUSIONS: Semaglutide, added to basal insulin, significantly reduced HbA1c and body weight in patients with uncontrolled T2D vs placebo.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Rodbard HW, Lingvay I, Reed J, et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. J Clin Endocrinol Metab. 2018. PMID: 29688502. doi:10.1210/jc.2018-00070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。